SCHEMBL10125872

SCHEMBL10125872

Cc1ccc(C)c2oc(-c3ccc(-c4ccc(-c5nc6ccccc6nc5-c5ccccc5)cc4)cc3)nc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.51
PDE10A Q9Y233 1/20 0.45
DHODH Q02127 2/20 0.45
KDM4E B2RXH2 8/20 0.44
ALDH1A1 P00352 6/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
LMNA P02545 3/20 0.44
RARA P10276 3/20 0.44
RARB P10826 3/20 0.44
RARG P13631 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
AKT1 P31749 1/20 0.42
AKT2 P31751 1/20 0.42
HPGD P15428 3/20 0.42
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126037 0.97 TDP1 (0.46) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL18873093 0.87 RARA (0.50) DHODHKDM4EALDH1A1RARARARB
SCHEMBL10125851 0.84 DHODH (0.56) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL10125860 0.82 TDP1 (0.50) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL10126027 0.81 DHODH (0.51) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL13621028 0.80 RARA (0.46) DHODHKDM4EALDH1A1LMNARARA
SCHEMBL10126032 0.79 CEPT1 (0.48) TDP1PDE10AKDM4EALDH1A1NPSR1
SCHEMBL10125805 0.78 NPC1 (0.54) KDM4EALDH1A1NPSR1MEN1KMT2A
SCHEMBL10125877 0.77 AKT1 (0.46) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL10125863 0.77 DHODH (0.45) TDP1DHODHKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 TDP1 2069/4885PDE10A 1974/4885DHODH 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.